About
People
Portfolio
News
Contact
Careers
More
PRESS RELEASE
NOV 21, 2022
EmbarkNeuro Announces Initiation of Phase 2 Trial of ANC-501, a First-In-Class, V1b Receptor Antagonist for the Personalized Treatment of Depression
SEP 7, 2021
Via Nova Therapeutics Announces $20 Million Series A Financing from Aditum Bio to Advance Four Antiviral Programs
DEC 15, 2020
Aditum Bio Announces Formation of Third Company, Anteris Bio
IN THE NEWS
NOV 2, 2020
Japan’s Sosei allies with ex-Novartis team to develop neurological drug pipeline
‘Stealth’ VC firm Aditum Bio launches its second biotech startup
NOV 14, 2021
Aditum Bio Announces Formation of Motric Bio, Focused on Spasticity Associated with Neurological Injuries and Disease
AUG 31, 2021
Versanis Bio Announces $70 million Series A Financing to Advance Bimagrumab for the Treatment of Obesity
NOV 3, 2020
Novartis vets Jimenez, Fishman thread digital into fabric of new VC firm Aditum, launch Tempero
Novartis alums Jimenez, Fishman unveil their next act: Aditum Bio
NOV 8, 2021
Aditum Bio announces the appointment of Stephen Kanes, M.D. Ph.D., as Chief Executive Officer of Ancora Bio
JUN 30, 2021
Aditum Bio Announces Formation of Ancora Bio, to Focus on Treatment-Resistant Depression
Aditum Bio, Co-Founded by Novartis Veterans Joe Jimenez and Dr. Mark Fishman, forms Second Company
Joe Jimenez has one more thing to do in biopharma. And now he and Mark Fishman have a $133M stake to play the startup game
